25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Publication number: 20140221287Abstract: There are provided polypeptide conjugates having enhanced duration of biological activity, and methods of use thereof. The polypeptide conjugates include duration enhancing moieties, including water soluble polymers, bound to the polypeptide components of defined sequence. Methods of use are provided for treatment of metabolic disorders. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyper lipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis, osteoarthritis, or short bowel syndrome.Type: ApplicationFiled: May 24, 2012Publication date: August 7, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Chengzao Sun, Manoj P. Samant, Swetha Neravetla
-
Publication number: 20140221607Abstract: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.Type: ApplicationFiled: June 8, 2012Publication date: August 7, 2014Applicant: Indiana University Research and Technology Corp.Inventors: Matthias Clauss, Irina Petrache, Robert Voswinckel
-
Publication number: 20140221271Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.Type: ApplicationFiled: June 5, 2012Publication date: August 7, 2014Inventors: Shawn P Iadonato, Eric J Tarcha
-
Publication number: 20140221273Abstract: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.Type: ApplicationFiled: April 16, 2012Publication date: August 7, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Suzanne M.J. Fleiszig, David J. Evans, Kwai Ping Tam, James J. Mun
-
Publication number: 20140221291Abstract: Factor V peptides and methods of use thereof are disclosed.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Inventors: Rodney M. Camire, Matthew W. Bunce, Mettine H.A. Bos
-
Patent number: 8796416Abstract: Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.Type: GrantFiled: October 25, 2011Date of Patent: August 5, 2014Assignee: Questcor Pharmaceuticals, IncInventors: Steve Cartt, Rujun Gong
-
Patent number: 8796414Abstract: Disclosed are compositions relating to novopeptides identified by the presence of frameshift mutations in tumor genes previously not identified as being oncogenic. The disclosed peptides can be used in the disclosed methods for the treatment of cancer.Type: GrantFiled: March 21, 2011Date of Patent: August 5, 2014Inventor: Stephen A. Johnston
-
Patent number: 8796415Abstract: A peptide including the amino acids sequence X9CGYX13X14AX16X17X18MX20X21X22X23X24X25X26X27CPLCX32X33, a nucleic acid coding for the peptide, and/or a recombinant vector including the nucleic acid for the preparation of a drug intended for the treatment of cancer.Type: GrantFiled: October 22, 2009Date of Patent: August 5, 2014Assignees: Centre National de la Recherche Scientifique, Universite Montpellier 2—Sciences et TechniquesInventors: Anne Debant, Susanne Schmidt, Nathalie Bouquier, Sylvie Fromont
-
Patent number: 8796226Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: August 19, 2010Date of Patent: August 5, 2014Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Publication number: 20140213663Abstract: The objective to be solved by the present invention is to provide a novel ice crystallization inhibitor which is industrially useful, which can be efficiently and stably produced in a safe process suitable for a food production without difficulty and which has excellent functions and properties. Also, the objective of the present invention is to provide an antibody which specifically reacts with the ice crystallization inhibitor, and a composition, a food, a biological sample protectant and a cosmetic which contain the ice crystallization inhibitor. Furthermore, the objective of the present invention is to provide a peptide which gives an indication of a protein having an ice crystallization inhibitory activity. The ice crystallization inhibitor according to the present invention is characterized in comprising a seed protein derived from a plant belonging to genus Vigna in Leguminosae, an allied species thereof or an improved species thereof.Type: ApplicationFiled: March 2, 2012Publication date: July 31, 2014Inventors: Hidehisa Kawahara, Hideaki Kegasa, Naoki Arai
-
Publication number: 20140212888Abstract: A method has been developed to efficiently proliferate and culture a CTL specific to WT1 peptides under limiting dilution conditions. Utilizing this method, CTLs capable of recognizing both a state where a wildtype WT1 specific peptide is presented by HLA-A*24:02 and a state where a mutant WT1 specific peptide is presented by HLA-A*24:02 have been successfully obtained.Type: ApplicationFiled: August 28, 2013Publication date: July 31, 2014Applicant: Medical & Biological Laboratories Co., Ltd.Inventors: Kazue WATANABE, Shingo TOJI
-
Publication number: 20140213759Abstract: A process for extraction of a peptide from a reaction mixture resulting from a peptide coupling reaction, the reaction mixture containing the peptide and a polar aprotic solvent selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide and N-methyl-2-pyrrolidone, whereby the process includes a step a) and a step b): step a) including the addition of a component a1) and a component a2), whereby component a1) is 2-methyltetrahydrofuran and component a2) is water, to the reaction mixture, so that a biphasic system with an organic layer and an aqueous layer is obtained; step b) including the subsequent separation of the organic layer containing the peptide from the aqueous layer. In an embodiment, a combination of 2-methyltetrahydrofuran and an organic solvent 1 selected from the group consisting of n-heptane, toluene, ethylacetate, isopropylacetate, acetonitrile and tetrahydrofuran is used for the process for extraction.Type: ApplicationFiled: June 14, 2012Publication date: July 31, 2014Applicants: LONZA BRAINE S.A., LONZA LTDInventors: Didier Monnaie, Luciano Forni, Mathieu Giraud
-
Publication number: 20140212448Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: December 11, 2013Publication date: July 31, 2014Applicant: VALNEVA AUSTRIA GMBHInventors: SHARMILA BAKSHI, THOMAS CIPPS, MARKUS HANER, JUTTA PIKALO, CHRISTINA SATKE, ESZTER NAGY, URBAN LUNDBERG, DAGMAR ZIERER, ANDREAS MEINKE, BIRGIT NOIGES, ULRIKE STIERSCHNEIDER, ALEXANDER VON GABAIN
-
Publication number: 20140213505Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Inventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Publication number: 20140212451Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Christopher G. Earnhart, Richard T. Marconi
-
Publication number: 20140212481Abstract: The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta42. The invention further relates to antibodies that bind to the Abeta(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention also relates to methods for designing small molecule inhibitors of amyloid deposition.Type: ApplicationFiled: April 7, 2014Publication date: July 31, 2014Inventors: Peter H. St. George-Hyslop, JoAnne McLaurin
-
Patent number: 8791232Abstract: An amino acid sequence is described. The amino acid may comprise a signal sequence that is SEQ ID NO. 1a (or a variant or homologue or derivative or fragment thereof) that is expressed as a fusion protein that comprises a protein of interest. The signal sequence directs secretion of the protein of interest. The protein of interest may be a heterologous protein. Secretion of the fusion protein aids purification.Type: GrantFiled: October 29, 2010Date of Patent: July 29, 2014Assignee: Dupont Nutrition Biosciences APSInventors: Patrick Maria Franciscus Derkx, Harm Mulder, Igor Nikolaev
-
Publication number: 20140206837Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: February 26, 2014Publication date: July 24, 2014Applicant: BRACCO SUISSE SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20140206628Abstract: Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: University of Washington through its Center for CommercializationInventors: David BAKER, Timothy A. WHITEHEAD, Sarel FLEISHMAN
-
Patent number: 8785391Abstract: An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.Type: GrantFiled: June 24, 2010Date of Patent: July 22, 2014Assignee: Alphabeta ABInventor: Jan Johansson
-
Patent number: 8785399Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antimicrobial activity, particularly against Gram-positive and Gram-negative bacteria. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, for use as a disinfectant and/or detergent or for use as a preservative.Type: GrantFiled: June 2, 2009Date of Patent: July 22, 2014Assignee: Spiderbiotech S.R.A.Inventors: Andrea Giuliani, Giovanna Pirri, Silvia Fabiole Nicoletto
-
Publication number: 20140199682Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing agents against influenza A viruses, and to the neutralizing agents produced. In particular, the invention concerns neutralizing agents against various influenza A virus subtypes, and methods and means for making such agents.Type: ApplicationFiled: November 17, 2011Publication date: July 17, 2014Applicant: SEA LANE BIOTECHNOLOGIES, LLCInventors: Lawrence Horowitz, Ramesh R. Bhatt, Arun K. Kashyap
-
Publication number: 20140199325Abstract: The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of SEQ ID NO: 1, The invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same.Type: ApplicationFiled: April 30, 2012Publication date: July 17, 2014Applicant: AstonUniversityInventors: Russell Collighan, Martin Griffin, Kamila Pytel, Zhuo Wang
-
Publication number: 20140199309Abstract: The invention provides methods for treating HIF-1?-overexpressing human tumors, inhibiting HIF-1?-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90? from the tumors.Type: ApplicationFiled: March 25, 2014Publication date: July 17, 2014Applicant: University of Southern CaliforniaInventors: Wei Li, David T. Woodley, Mei Chen
-
Publication number: 20140200187Abstract: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: XIGEN INFLAMMATION LTD.Inventor: Christophe Bonny
-
Publication number: 20140199333Abstract: The present disclosure provides human Aquaporin 4 (AQP4) peptides and peptides having homology to human Aquaporin 4 (AQP4) peptides. Also provided herein are methods for using human AQP4 peptides and peptides homologous to human AQP4 peptides for diagnosing and/or treating Neuromyelitis Optica.Type: ApplicationFiled: December 10, 2013Publication date: July 17, 2014Applicant: The Regents of the University of CaliforniaInventors: Scott S. Zamvil, Michel Varrin-Doyer, Bruce Anthony Campbell Cree
-
Patent number: 8779093Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.Type: GrantFiled: September 10, 2009Date of Patent: July 15, 2014Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel
-
Patent number: 8778886Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.Type: GrantFiled: February 26, 2010Date of Patent: July 15, 2014Assignee: Tufts UniversityInventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read
-
Publication number: 20140193450Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.Type: ApplicationFiled: June 11, 2012Publication date: July 10, 2014Applicant: BIOMAY AGInventors: Katarzyna Niespodziana, Margarete Focke-Tejkl, Susanne Vrtala, Srinita Banerjee, Kuan-Wei Chen, Milena Weber, Rudolf Valenta, Katharina Marth
-
Publication number: 20140194593Abstract: The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.Type: ApplicationFiled: January 31, 2013Publication date: July 10, 2014Applicant: Yeda Research and Development Co., Ltd.Inventors: Alexander Gad, Dora Lis
-
Publication number: 20140193844Abstract: There is described herein methods and peptides for detecting autoantibodies to NOG and/or SOST in a patient sample in order to diagnose of prognosticate Ankylosing Spondylitis in the patient.Type: ApplicationFiled: July 12, 2012Publication date: July 10, 2014Applicant: UNIVERSITY HEALTH NETWORKInventors: Florence Wing Ling Tsui, Robert Davies Inman
-
Publication number: 20140194344Abstract: The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.Type: ApplicationFiled: April 23, 2012Publication date: July 10, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Daniel H. Fine, Kabilan Velliyagounder
-
Publication number: 20140194347Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON
-
Publication number: 20140196172Abstract: Provided are organelle targeting nanocarriers, including peptides, which act to deliver biological molecules such as nucleic acids to non-nuclear organelles such as mitochondria and chloroplasts. Also provided are methods for genetic transformation of non-nuclear organelles using such nanocarriers.Type: ApplicationFiled: August 2, 2012Publication date: July 10, 2014Inventors: Francois Eudes, Trevor Macmillan
-
Publication number: 20140193417Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: September 26, 2013Publication date: July 10, 2014Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 8772236Abstract: The invention relates to the fields of protein chemistry, biology and medicine. More specifically, it relates to the design and preparation of proteinmimics of members of the cystine-knot growth factor superfamily. Further, the invention relates to the use of these proteinmimics as a medicament or prophylactic agent. The invention provides proteinmimics of members of the cystine-knot growth factor superfamily, preferably for use in immunogenic and/or therapeutic compositions.Type: GrantFiled: February 5, 2010Date of Patent: July 8, 2014Assignees: Pepscan Systems B.V., Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Peter Timmerman, Wouter C. Puijk, Tilman M. Hackeng, Arjan W. Griffioen
-
Patent number: 8772229Abstract: The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus.Type: GrantFiled: September 18, 2009Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Philip A. Cole, Bradley P. Barnett, Yousang Hwang, Jef D. Boeke
-
Patent number: 8772447Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: July 27, 2012Date of Patent: July 8, 2014Assignee: GE Healthcare Bio-Sciences ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 8772232Abstract: Novel protracted exendin-4 compounds and therapeutic uses thereof.Type: GrantFiled: August 18, 2011Date of Patent: July 8, 2014Assignee: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen
-
Publication number: 20140187476Abstract: This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: June 25, 2013Publication date: July 3, 2014Applicant: BAOBAB PHARMACEUTICALS LIMITEDInventors: Dong XIE, He JIANG
-
Publication number: 20140187743Abstract: The present invention relates to a membrane having bound thereto an antibacterial peptide that binds to collagen, and more particularly to a collagen membrane comprising a fusion peptide of a collagen-binding peptide and an antibacterial peptide, fixed to the collagen surface. The present invention provides a collagen membrane having surface activity by a fusion peptide bound to the surface thereof. When the collagen membrane is transplanted in vivo, the retention time of the fusion peptide in a local region can increase, and the fusion peptide can promote the cell migration, proliferation and differentiation associated with bone tissue regeneration, thereby maximizing the ability to regenerate bone tissue. Thus, the collagen membrane contributes to the development of therapeutic technology for bone induction and regeneration. Also, the fusion peptide may be applied to other types of graft materials made of collagen.Type: ApplicationFiled: December 16, 2011Publication date: July 3, 2014Applicant: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, In Kyong Shim, Hyun Jung Park
-
Publication number: 20140186350Abstract: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.Type: ApplicationFiled: December 17, 2013Publication date: July 3, 2014Inventors: Joy GHOSH, Michael ROGUSKA, Andrew Anh NGUYEN, Thomas PIETZONKA, Stephen POOR, Matthais MACHACEK, Chad BIGELOW
-
Publication number: 20140187493Abstract: The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: SORICIMED BIOPHARMA INC.Inventor: John M. Stewart
-
Publication number: 20140187484Abstract: A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.Type: ApplicationFiled: March 3, 2014Publication date: July 3, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Zhichuan Li, Joseph I. Shapiro
-
Publication number: 20140187502Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: ApplicationFiled: November 12, 2013Publication date: July 3, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Publication number: 20140187744Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. In one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino add sequence of SEQ ID NO: 4.Type: ApplicationFiled: August 9, 2012Publication date: July 3, 2014Applicant: NIPRO CORPORATIONInventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
-
Patent number: 8765677Abstract: This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine; Xaa2 is selected from arginine and lysine; Xaa5 is selected from aspartic acid and glutamic acid; and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.Type: GrantFiled: September 21, 2010Date of Patent: July 1, 2014Assignees: The University of Queensland, The University of SydneyInventors: Richard Lewis, David John Adams, Geza Berecki, Roger Drinkwater, Paul Francis Alewood, MacDonald James Christie
-
Patent number: 8765686Abstract: Isolated polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection, or to diagnose or monitor progression of an influenza infection are described.Type: GrantFiled: August 3, 2011Date of Patent: July 1, 2014Assignee: University of Washington through its Center for CommercializationInventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
-
Patent number: 8765673Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.Type: GrantFiled: January 4, 2012Date of Patent: July 1, 2014Assignee: Arizona Board of RegentsInventors: Colleen Brophy, Alyssa Panitch, Catherine Parmiter, Elizabeth Furnish, Padmini Komalavilas
-
Patent number: 8765680Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: GrantFiled: December 18, 2013Date of Patent: July 1, 2014Assignee: Jazz Pharmaceuticals International LimitedInventors: David J. Ellis, George P. Miljanich, David E. Shields